biotech / news / / Benzinga
Moderna stock is showing upward bias.
Moderna's stock is currently trading 2.7% below its 20-day SMA and 4.8% below its 50-day SMA.
KEY POINTS
- A golden cross formed in January but near-term moving averages suggest a paused uptrend.
- Moderna's mRNA-1010 flu vaccine Phase 3 results are seen as critical for non-pandemic revenue prospects.
- Key technical levels are $47.50 as support and $55.00 as resistance for MRNA stock.
COMPANIES
Summarized by Newsio from Benzinga. How we summarize →